Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

NCT05130177 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Zimberelimab
DRUG: Domvanalimab

Sponsor

Diwakar Davar

Collaborators

[object Object]